Search research articles
Contact Us
Filters
Showing results (61-70 of 119) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2016
Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours
Didier Frappaz, Sara M Federico, Andrew D J Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2013
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors
Lia Gore, Tanya M Trippett, Howard M Katzenstein, et al.
Anti-Cancer Drugs
|
November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
D Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Pediatric Blood & Cancer
|
August 8, 2023
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)
Elizabeth A Raetz, David T Teachey, Charles Minard, et al.
Cancer Chemotherapy and Pharmacology
|
March 6, 2008
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
Laura Q M Chow, Daniel L Gustafson, Cindy L O'Bryant, et al.
Pediatric Blood & Cancer
|
April 15, 2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)
Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2022
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma
Erica Brivio, André Baruchel, Auke Beishuizen, et al.
Neuro-Oncology
|
May 22, 2014
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma
Ute Bartels, Johannes Wolff, Lia Gore, et al.
Blood
|
May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T Teachey, Susan R Rheingold, Shannon L Maude, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 119) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2016
Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours
Didier Frappaz, Sara M Federico, Andrew D J Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2013
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors
Lia Gore, Tanya M Trippett, Howard M Katzenstein, et al.
Anti-Cancer Drugs
|
November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
D Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Pediatric Blood & Cancer
|
August 8, 2023
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)
Elizabeth A Raetz, David T Teachey, Charles Minard, et al.
Cancer Chemotherapy and Pharmacology
|
March 6, 2008
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
Laura Q M Chow, Daniel L Gustafson, Cindy L O'Bryant, et al.
Pediatric Blood & Cancer
|
April 15, 2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)
Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2022
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma
Erica Brivio, André Baruchel, Auke Beishuizen, et al.
Neuro-Oncology
|
May 22, 2014
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma
Ute Bartels, Johannes Wolff, Lia Gore, et al.
Blood
|
May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T Teachey, Susan R Rheingold, Shannon L Maude, et al.
Page
of 12